Trial reportEuropean journal of pain (London, England)2020
The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.
Trial report in European journal of pain (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 6 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review.Frontiers in pharmacology · 2024Pooled it
- Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis.PloS one · 2023Pooled it
- The effect of medical cannabis on cognitive functions: a systematic review.Systematic reviews · 2022Pooled it
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition.Pain medicine (Malden, Mass.) · 2022Guideline
- Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022Pooled it
- Efficacy of ultrasound-guided myofascial hydrodissection technique in myofascial pain syndrome of upper trapezius: a randomized controlled trial.Scientific reports · 2025Trial
- Immediate efficacy of low-intensity focused ultrasound versus planar ultrasound in patients with myofascial pain syndrome of upper trapezius: a randomized controlled clinical trial.BMC musculoskeletal disorders · 2025Trial
- The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.European journal of pain (London, England) · 2020Trial
- Glucocorticoid-endocannabinoid crosstalk in the ventrolateral periaqueductal gray (vlPAG) promotes pain resolution.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Ultrasound-guided platelet-rich plasma myofascial injection for chronic low back pain: a retrospective study.BMC musculoskeletal disorders · 2026Article
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review.Drug and alcohol review · 2026Review
- Glucocorticoid-endocannabinoid crosstalk in the ventrolateral periaqueductal gray (vlPAG) promotes pain resolution.bioRxiv : the preprint server for biology · 2026Article
- Cannabinoid efficacy for pain: dose, chronicity and route.Frontiers in neuroscience · 2026Review
- Adverse events associated with medical cannabis reported within a centralized call center.Frontiers in pharmacology · 2026Article
- Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Response to Barner et al. (2025) on comment on Zabik et al. (2024): special considerations for cannabis research in RCTs and feasibility in a clinical setting.Psychopharmacology · 2026Article
- Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- ABCB1 polymorphisms are associated with clinical response to nabiximols in patients with multiple sclerosis-related spasticity.Journal of cannabis research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecise cannabis treatment dosing remains a major challenge, leading to physicians' reluctance to prescribe medical cannabis.
objectiveTo test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative medical device that enables the delivery of inhaled therapeutic doses of Δ
methodsIn a randomized, three-arms, double-blinded, placebo-controlled, cross-over trial, 27 patients received a single inhalation of Δ
resultsFollowing inhalation of 0.5 mg or 1mg, Δ
conclusionThis feasibility trial demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses, produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/ complex-regional pain syndrome (CRPS). Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models. SIGNIFICANCE: Evidence suggests that cannabis-based medicines are an effective treatment for chronic pain in adults. The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes rapid onset of analgesia. However, currently used routes of cannabinoids delivery provide unknown doses, making it impossible to implement a pharmaceutical standard treatment plan. A novel selective-dose cannabis inhaler delivers significantly low and precise doses of THC, thus allowing the administration of inhaled cannabis-based medicines according to high pharmaceutical standards. These low doses of THC can produce safe and effective analgesia in patients with chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.